HC Wainwright Has Positive Outlook for ALGS Q3 Earnings

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Research analysts at HC Wainwright increased their Q3 2026 EPS estimates for Aligos Therapeutics in a research note issued to investors on Monday, August 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($2.81) per share for the quarter, up from their previous estimate of ($3.16). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($7.14) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q4 2026 earnings at ($2.02) EPS, FY2026 earnings at ($7.41) EPS, Q1 2027 earnings at ($1.49) EPS, Q2 2027 earnings at ($1.50) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($0.40) EPS, FY2027 earnings at ($4.02) EPS, FY2028 earnings at ($2.85) EPS, FY2029 earnings at ($2.36) EPS and FY2030 earnings at ($0.71) EPS.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.95. The firm had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%.

ALGS has been the topic of several other research reports. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. Lake Street Capital initiated coverage on Aligos Therapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $45.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a report on Friday, May 29th. Finally, Weiss Ratings lowered Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Aligos Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Price Performance

Shares of Aligos Therapeutics stock opened at $7.28 on Wednesday. The business has a 50-day moving average of $5.41 and a 200-day moving average of $6.40. The company has a market capitalization of $45.06 million, a PE ratio of -1.00 and a beta of 2.31. Aligos Therapeutics has a 1-year low of $3.98 and a 1-year high of $13.69.

Institutional Investors Weigh In On Aligos Therapeutics

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in Aligos Therapeutics in the fourth quarter worth about $226,000. HRT Financial LP acquired a new stake in Aligos Therapeutics during the fourth quarter valued at approximately $106,000. DRW Securities LLC acquired a new stake in Aligos Therapeutics during the fourth quarter valued at approximately $111,000. LPL Financial LLC lifted its holdings in Aligos Therapeutics by 19.7% during the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after buying an additional 10,880 shares during the last quarter. Finally, Two Sigma Investments LP lifted its holdings in Aligos Therapeutics by 223.0% during the 3rd quarter. Two Sigma Investments LP now owns 38,995 shares of the company’s stock worth $382,000 after buying an additional 26,922 shares during the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

More Aligos Therapeutics News

Here are the key news stories impacting Aligos Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Aligos’ third and fourth quarters of 2026 to losses of $2.81 and $2.02, respectively, from losses of $3.16 and $2.22. It also improved its FY2026 estimate to a $7.41 loss from a $8.42 loss. Smaller projected losses generally indicate improving financial expectations. HC Wainwright Aligos earnings estimates
• Positive Sentiment: The analyst raised estimates for the third quarter of 2027, fourth quarter of 2027 and fiscal 2030, while retaining a Buy rating. These changes suggest HC Wainwright sees potential for operating improvement over time, even though profitability remains distant. HC Wainwright Aligos forecast revisions
• Neutral Sentiment: Aligos’ shares opened at $7.28, with a market capitalization of approximately $45 million. The stock remains highly volatile, with a beta of 2.31, and is trading above its 50-day moving average but near its 200-day moving average.
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from July 27, with a zero-day days-to-cover ratio. The figures provide no evidence of meaningful short-selling pressure, although the reported “NaN” percentage change suggests a data-quality issue.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for the first and second quarters of 2027 and reduced full-year estimates for 2027, 2028 and 2029. The FY2027 forecast fell to a $4.02 loss from $3.56, while FY2028 and FY2029 estimates also worsened, signaling that sustained losses may persist longer than previously expected. HC Wainwright Aligos long-term earnings estimates

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.